OncLive and Targeted Oncology: Drug yields long-lasting benefits to treat PEComa tumors
OncLive and Targeted Oncology covered research presented by the University of Cincinnati's Thomas Herzog that found patients with perivascular epithelioid sarcoma (PEComa) of gynecologic or peritoneal origin experienced rapid, durable responses when treated with the drug nab-sirolimus.
At the 2024 SGO Annual Meeting on Women's Cancer, Herzog presented results from a subgroup analysis of the phase 2 AMPECT trial. Nab-sirolimus is the first and only FDA-approved treatment for advanced PEComa.
"The median time to response was extremely fast, about 1.4 months, and the duration of response was a little over 36 months," Herzog, MD, a University of Cincinnati Cancer Center member, the Paul and Carolyn Flory Professor in Gynecologic Oncology in the UC College of Medicine and director of UC Health’s Gynecologic Cancer Disease Center, told Targeted Oncology. "It is important to remember these responses occur often rapidly, and they are quite durable."
Watch the Targeted Oncology video.
Featured photo at top of Thomas Herzog. Photo provided.
Related Stories
Educating more nurses to meet a growing demand for quality healthcare
Richard Prior, senior associate dean for academic operations and accreditation, speaks with Fox 19 about growing enrollment at the UC College of Nursing for a recent health segment.
How to prevent social isolation at school
July 1, 2026
UC Professor Ashley Merianos talks to U.S. News & World Report about her study that found that excessive use of social media exacerbates feelings of loneliness among college students. UC is taking preventive steps to give students social outlets.
David Gius, MD, PhD, officially takes the helm as director of the University of Cincinnati Cancer Center
July 1, 2026
David Gius, MD, PhD, officially takes the helm as director of the University of Cincinnati Cancer Center, bringing a bold vision for elite cancer care.